From June 19-21, 2023, CPHI China 2023 took place at the Shanghai New International Expo Center. Renowned as a premier global exhibition in the pharmaceutical sector, this year's conference encompassed the entire pharmaceutical industry chain. With a vast exhibition area spanning 200,000 square meters, the event served as a professional and international platform for pharmaceutical companies and buyers from around the world to engage in meaningful discussions, emphasizing the latest advancements in pharmaceutical technology and products. Gan & Lee Pharmaceuticals (stock code: 603087. SH) showcased its comprehensive range of insulin preparations and devices at the event, effectively highlighting the company's remarkable accomplishments in R&D innovation, production technology, international commercialization, and other essential areas to industry peers, as well as domestic and international customers.

The Gan & Lee booth was thoughtfully designed to showcase the distinctive unique shapes of products. The exhibition featured the company's six core insulins, two pre-filled pens, reusable insulin pens, and pen needles. The diverse range of offerings garnered significant attention from industry professionals worldwide, as well as prospective customers, affirming their appreciation for the extensive product portfolio.

Gan & Lee attaches great importance to customer needs. CEO Du Kai personally attended the exhibition and engaged in extensive discussions with both new and existing customers at the company's booth. Through face-to-face interactions, Gan & Lee's international business affairs team delved deeper into market demands and industry trends, fostering meaningful dialogue with customers. The team not only shared positive insights and information but also established stronger partnerships, conveying Gan & Lee's unwavering commitment to fostering cooperation and pursuing opportunities in the global market.

It is worth mentioning that under the leadership of Mr. Du Kai, the international business affairs team held significant meetings with key customers, resulting in a mutually agreed cooperation intention for an insulin project. In the presence of government officials, both parties signed a memorandum of understanding on the spot, marking a momentous milestone. The meeting yielded remarkable outcomes, and Mr. Du Kai expressed his gratitude for the governmental support, which added significant impetus to this collaboration. He eagerly anticipates the swift implementation of the insulin project, contributing to the thriving development of the bilateral pharmaceutical industry.

Throughout the exhibition, Gan & Lee's international business affairs team cordially welcomed numerous attendees, engaging in fruitful discussions regarding business cooperation and market prospects with customers from various countries. These interactions not only fostered a deeper mutual understanding but also established a strong groundwork for future collaborations, thus expanding Gan & Lee's business network within the international pharmaceutical community. Moving forward, the company remains dedicated to driving drug development and innovation, bolstering international expansion efforts, actively participating in global pharmaceutical industry cooperation and exchanges, and eagerly anticipating the exploration of new opportunities in the pharmaceutical field alongside esteemed industry colleagues and customers.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.